Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Caspofungin (Cancidas) vs Ecallantide (Kalbitor)
An educational, source-based comparison of Caspofungin (Cancidas) and Ecallantide (Kalbitor) — how each peptide works, what it's researched for, and what to know before going deeper.
Echinocandin lipopeptide for invasive Candida and Aspergillus infections.
Semi-synthetic lipopeptide that inhibits β-1,3-D-glucan synthase, disrupting fungal cell wall integrity. First echinocandin approved.
- Invasive candidiasis
- Invasive aspergillosis (salvage)
- Empiric antifungal in febrile neutropenia
- • FDA-approved.
- • Hepatic dose adjustment; few drug interactions.
Plasma kallikrein inhibitor for hereditary angioedema.
60-amino-acid recombinant protein that selectively inhibits plasma kallikrein, reducing bradykinin generation during HAE attacks.
- Hereditary angioedema (acute attacks, ≥12 yrs)
- • FDA-approved.
- • Boxed warning: anaphylaxis — administer by healthcare professional.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Caspofungin (Cancidas) | Caspofungin vs amphotericin B for invasive candidiasis | NEJM | 2002 | Comparable efficacy with better tolerability. |
| Ecallantide (Kalbitor) | EDEMA trials | NEJM | 2010 | Improved HAE attack resolution vs placebo. |
Side-effect & safety grid
- FDA-approved.
- Hepatic dose adjustment; few drug interactions.
- FDA-approved.
- Boxed warning: anaphylaxis — administer by healthcare professional.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Caspofungin (Cancidas) vs Ecallantide (Kalbitor) — Key differences
- Class: Caspofungin (Cancidas) is classified as Echinocandin · Antifungal, while Ecallantide (Kalbitor) is Kallikrein Inhibitor · Immunology.
- Primary research focus: Caspofungin (Cancidas) — invasive candidiasis; Ecallantide (Kalbitor) — hereditary angioedema (acute attacks, ≥12 yrs).
- Tag: FDA-Approved · Antifungal vs FDA-Approved · Rare Disease.